^
    Back
    Association details:
    Biomarker:MAF1 expression
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    PLoS One
    Title:

    MAF1 is a predictive biomarker in HER2 positive breast cancer

    Published date:
    10/06/2023
    Excerpt:
    In HER2-positive breast cancer patients, MAF1 expression significantly increases and correlates with five years of relapse-free survival in response to trastuzumab treatment, suggesting MAF1 is a predictive biomarker in breast cancer.
    DOI:
    10.1371/journal.pone.0291549